Status
Conditions
Treatments
About
This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Julie Krystal, MD, MPH; Jonathan Fish, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal